BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23219291)

  • 21. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre.
    Anfinan N; Sait K; Ghatage P; Nation J; Chu P
    Arch Gynecol Obstet; 2011 Sep; 284(3):731-5. PubMed ID: 20963432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors and survival of borderline ovarian tumors in Rajavithi Hospital between 1979-2006 A.D.
    Sornsukolrat S; Tuipae S
    J Med Assoc Thai; 2012 Sep; 95(9):1141-8. PubMed ID: 23140030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Retrospective analysis of the clinical outcomes in 12 recurrent borderline ovarian tumor patients with second fertility-sparing surgery].
    Chen R; Zhu T; Yu H; Zhu J; Lu X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Apr; 49(4):254-9. PubMed ID: 24969331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801).
    Tang A; Kondalsamy-Chennakesavan S; Ngan H; Zusterzeel P; Quinn M; Carter J; Leung Y; Obermair A
    Gynecol Oncol; 2012 Jul; 126(1):36-40. PubMed ID: 22370601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of restaging borderline ovarian tumors: single institution experience and review of the literature.
    Zapardiel I; Rosenberg P; Peiretti M; Zanagnolo V; Sanguineti F; Aletti G; Landoni F; Bocciolone L; Colombo N; Maggioni A
    Gynecol Oncol; 2010 Nov; 119(2):274-7. PubMed ID: 20797775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
    Suh-Burgmann E
    Gynecol Oncol; 2006 Dec; 103(3):841-7. PubMed ID: 16793124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
    Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
    du Bois A; Ewald-Riegler N; de Gregorio N; Reuss A; Mahner S; Fotopoulou C; Kommoss F; Schmalfeldt B; Hilpert F; Fehm T; Burges A; Meier W; Hillemanns P; Hanker L; Hasenburg A; Strauss HG; Hellriegel M; Wimberger P; Keyver-Paik MD; Baumann K; Canzler U; Wollschlaeger K; Forner D; Pfisterer J; Schröder W; Münstedt K; Richter B; Kommoss S; Hauptmann S;
    Eur J Cancer; 2013 May; 49(8):1905-14. PubMed ID: 23490647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective evaluation of tumor markers in ovarian mature cystic teratoma and ovarian endometrioma.
    Kataoka T; Watanabe Y; Hoshiai H
    J Obstet Gynaecol Res; 2012 Aug; 38(8):1071-6. PubMed ID: 22568880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistological analysis of stress-induced phosphoprotein 1 in ovarian cancer patients with low serum cancer antigen 125 levels.
    Chao A; Lee LY; Hsueh C; Lin CY; Tsai CL; Chao AS; Lin CT; Chou HH; Chang TC; Wang TH
    Taiwan J Obstet Gynecol; 2013 Jun; 52(2):185-91. PubMed ID: 23915849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study.
    Guvenal T; Dursun P; Hasdemir PS; Hanhan M; Guven S; Yetimalar H; Goksedef BP; Sakarya DK; Doruk A; Terek MC; Saatli B; Guzin K; Corakci A; Deger E; Celik H; Cetin A; Ozsaran A; Ozbakkaloglu A; Kolusari A; Celik C; Keles R; Sagir FG; Dilek S; Uslu T; Dikmen Y; Altundag O; Ayhan A
    Gynecol Oncol; 2013 Dec; 131(3):546-50. PubMed ID: 24016409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors predicting recurrence in borderline ovarian tumors.
    Wu TI; Lee CL; Wu MY; Hsueh S; Huang KG; Yeh CJ; Lai CH
    Gynecol Oncol; 2009 Aug; 114(2):237-41. PubMed ID: 19481786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
    Ma SK; Zhang HT; Wu LY; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The clinical features and management of borderline ovarian tumors].
    Zhang Z; Hong W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 1998 Sep; 33(9):556-9. PubMed ID: 10806735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presence of a sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mullerian tumors: a clinicopathologic study of 47 cases.
    Kunkel J; Peng Y; Tao Y; Krigman H; Cao D
    Am J Surg Pathol; 2012 Jun; 36(6):831-7. PubMed ID: 22588065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
    Fotopoulou C; Sehouli J; Ewald-Riegler N; de Gregorio N; Reuss A; Richter R; Mahner S; Kommoss F; Schmalfeldt B; Fehm T; Hanker L; Wimberger P; Canzler U; Pfisterer J; Kommoss S; Hauptmann S; du Bois A;
    Int J Gynecol Cancer; 2015 Sep; 25(7):1248-52. PubMed ID: 25978292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocervical-like versus intestinal-type mucinous borderline ovarian tumors: a large retrospective series focusing on the clinicopathologic characteristics.
    Song T; Choi CH; Lee YY; Kim TJ; Lee JW; Sung CO; Song SY; Bae DS; Kim BG
    Gynecol Obstet Invest; 2013; 76(4):241-7. PubMed ID: 24192519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.